Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/301% below fair value
$9.61−0.62 (-6.06%)
Close on Nov 13, 2026Market cap $647.14MP/E –Yield –
Ginkgo Bioworks operating margin
Operating margin is operating income as a percentage of revenue.
Ginkgo Bioworks's operating margin for the twelve months ending Sep 30, 2026 was -204.5%. For fiscal 2025 it was -185.3%, against -246.5% the year before. The highest annual figure on record is -132.1% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -185.3% | +61.3 |
| FY2024 | Dec 31, 2024 | -246.5% | +97.2 |
| FY2023 | Dec 31, 2023 | -343.8% | +118.6 |
| FY2022 | Dec 31, 2022 | -462.4% | +120.2 |
| FY2021 | Dec 31, 2021 | -582.6% | −403.9 |
| FY2020 | Dec 31, 2020 | -178.8% | −46.6 |
| FY2019 | Dec 31, 2019 | -132.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -157.5% | +122.7 |
| Q2 FY2026 | Jun 30, 2026 | -290.5% | −141.8 |
| Q1 FY2026 | Mar 31, 2026 | -366.5% | −154.7 |
| Q4 FY2025 | Dec 31, 2025 | -148.0% | +88.3 |
| Q3 FY2025 | Sep 30, 2025 | -280.1% | −218.1 |
| Q2 FY2025 | Jun 30, 2025 | -148.6% | +248.0 |
| Q1 FY2025 | Mar 31, 2025 | -211.8% | +257.3 |
| Q4 FY2024 | Dec 31, 2024 | -236.3% | +276.2 |
| Q3 FY2024 | Sep 30, 2024 | -62.0% | +454.7 |
| Q2 FY2024 | Jun 30, 2024 | -396.7% | −168.1 |
| Q1 FY2024 | Mar 31, 2024 | -469.1% | −201.8 |
| Q4 FY2023 | Dec 31, 2023 | -512.5% | −277.6 |
| Q3 FY2023 | Sep 30, 2023 | -516.7% | +469.7 |
| Q2 FY2023 | Jun 30, 2023 | -228.6% | +219.4 |
| Q1 FY2023 | Mar 31, 2023 | -267.3% | +133.7 |
| Q4 FY2022 | Dec 31, 2022 | -234.9% | +899.7 |
| Q3 FY2022 | Sep 30, 2022 | -986.4% | −952.0 |
| Q2 FY2022 | Jun 30, 2022 | -447.9% | −310.5 |
| Q1 FY2022 | Mar 31, 2022 | -401.0% | −271.5 |
| Q4 FY2021 | Dec 31, 2021 | -1134.5% | −960.2 |
| Q3 FY2021 | Sep 30, 2021 | -34.4% | +224.3 |
| Q2 FY2021 | Jun 30, 2021 | -137.4% | – |
| Q1 FY2021 | Mar 31, 2021 | -129.5% | – |
| Q4 FY2020 | Dec 31, 2020 | -174.3% | – |
| Q3 FY2020 | Sep 30, 2020 | -258.7% | – |
See a number that looks wrong?